Histogenics Corp’s $17 Million Shares Offering

Gunderson Dettmer advised Histogenics Corporation on a follow-on public offering underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant, for a total of $17,000,750.00 in aggregate gross proceeds.

Canaccord Genuity LLC and BTIG, LLC acted as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as the co-manager for the offering.

Histogenics, which trades on The Nasdaq Capital Market under the ticker symbol “HSGX,” is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. The company, led by Adam Gridley, Jonathan I Lieber and Lynne Kelley, is based in Waltham (MA).

Gunderson Dettmer advised Histogenics Corporation with a team including Marc Dupre (Picture), of counsel Keith Scherer, and associates Albert Vanderlaan and Naomi Smith led the team advising Histogenics.

Involved fees earner: Marc Dupre – Gunderson Dettmer; Keith Scherer – Gunderson Dettmer; Albert Vanderlaan – Gunderson Dettmer; Naomi Smith – Gunderson Dettmer;

Law Firms: Gunderson Dettmer;

Clients: Histogenics Corporation;

Author: Ambrogio Visconti